Allergan, Inc., AGN and Medytox MMMS today announced that they
have entered into a license agreement pursuant to which, upon closing,
Allergan will pay Medytox an upfront payment of U.S. $65 million and
Medytox will grant Allergan exclusive rights, worldwide outside of
Korea, to develop and, if approved, commercialize certain neurotoxin
product candidates currently in development, including a potential
liquid-injectable product. Pursuant to the agreement, Allergan has also
agreed to make additional contingent payments, including up to an
aggregate of U.S. $116.5 million upon achieving certain development
milestones, up to an aggregate of U.S. $180.5 million upon achieving
certain commercialization milestones, and royalties on product sales. The
closing of the transaction is contingent on obtaining certain government
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in